Wegovy vs Mounjaro: 9 Key Differences To Know (2026)

Wegovy and Mounjaro are known for the reviews testified, and the results delivered. 

But they're not the same drug, and the differences matter.

This guide breaks down the key differences between Wegovy and Mounjaro:

• How Wegovy and Moujaro work
• What clinical trials show about weight loss results
• What each drug costs with and without insurance
• Which is right for your weight loss journey

Wegovy vs. Mounjaro: At a Glance

‍

‍

What Is Wegovy?

Wegovy is a once-weekly injectable medication made by Novo Nordisk. Its active ingredient is semaglutide, which is the same compound found in Ozempic. 

It works by mimicking the GLP-1 hormone, which slows digestion, reduces appetite, and helps regulate blood sugar.

What Is Mounjaro?

Mounjaro is a once-weekly injectable medication made by Eli Lilly. Its active ingredient, tirzepatide, makes it a dual-action drug that targets both the GLP-1 and GIP receptors in the body. 

Mounjaro is FDA-approved for the treatment of Type 2 diabetes. 

Similarities Between Wegovy and Mounjaro

Despite their differences, both drugs share a significant amount in common.

‍

‍

Key Differences Between Wegovy and Mounjaro

Here's where the two medications diverge.

Difference #1: FDA Approval and Intended Use

Wegovy is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, and other weight-related conditions like hypertension, sleep apnea, or type 2 diabetes.

Mounjaro is FDA-approved to treat type 2 diabetes. While it is not officially approved for weight loss under that brand name, clinicians may prescribe it off-label for weight management.

Difference #2: Insurance and Coverage

Mounjaro often has more coverage potential, especially for patients with type 2 diabetes, because insurers commonly include diabetes medications on their formularies.

Coverage for Wegovy is less consistent. Many insurance plans either restrict coverage for weight-loss medications or exclude them entirely, so eligibility and out-of-pocket costs can vary widely by insurer and plan.

Both brand-name drugs exceed $1,000 per month, making them difficult to maintain long-term before achieving consistent results.

That’s where alternatives like personalized GLP-1 injections become worth exploring, with Ivy Rx providing access to the same active ingredients at a lower cost and ongoing provider support.

Difference #3: Weight Loss Results Compared

Both drugs produce meaningful weight loss. The clinical data show a difference in averages, but averages don't tell the whole story.

Wegovy (semaglutide):

• 15% average body weight loss at 68 weeks (STEP 1 trial).
• About one-third of participants lost 20% or more of their body weight.
• Novo Nordisk is currently seeking approval for a higher dose of 7.2 mg, with early data showing an average 21–25% weight loss, which may narrow the current gap.

Mounjaro (tirzepatide):

• 15% average weight loss at the 5 mg dose.
• 19.5% at 10 mg.
• 20.9% at 15 mg (SURMOUNT-1 trial).
• Over 50% of participants at the highest dose lost more than 20% of their body weight.

Your provider can help you weigh the data against your specific weight loss goals.

Side Effects Compared

The side effect profiles are similar, but not identical.

Tirzepatide may produce more nausea at higher doses due to its dual receptor activity. However, this typically improves after the first few weeks as the body adjusts to titration.

Both drugs require a gradual dose increase to reduce GI side effects. Patients sensitive to standard dosing may benefit from a microdose GLP-1 approach, which starts at a lower entry point. 

Cost Comparison

Both manufacturers offer copay cards that may bring the monthly cost down to as little as $25 for patients with commercial insurance that covers the medication.

For those without coverage:

• Eli Lilly's savings program for Mounjaro runs ~$499 for a 28-day supply
• Novo Nordisk's equivalent for Wegovy is ~$349 per month

At list price, without any savings program, both drugs exceed $1,000 per month.

For a deeper breakdown, see how much tirzepatide costs with and without insurance.

How Wegovy and Mounjaro Are Administered

Both are once-weekly subcutaneous injections into the fat layer just beneath the skin. 

They also come in prefilled auto-injector pens designed for home use. The needles are short and thin, making administration painless. 

Wegovy vs Mounjaro Dosing Schedule

‍

‍

Dos and don'ts for Mounjaro and Wegovy 

Do:

• Inject into the abdomen, thigh, or upper arm and rotate injection sites weekly to avoid irritation.
• Store in the refrigerator (36°F–46°F); both can also be kept at room temperature up to 86°F.
• If you miss a Wegovy dose, take it within 5 days; after that, skip it and resume your schedule.
• If you miss a Mounjaro dose, take it within 4 days; after that, skip it and resume your schedule.

Don't:

• Inject into a vein or muscle.
• Use Mounjaro if the liquid appears cloudy or discolored.

Safety Considerations Before Starting Either Medication

Both drugs share important safety warnings your provider will review before prescribing.

1. Thyroid C-Cell Tumor Risk

Neither drug is recommended for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). 

2. Pancreatitis Risk

If you notice severe abdominal pain, especially pain that spreads to your back, stop the medication and contact your provider immediately. 

3. Gastrointestinal Intolerance

Nausea and GI symptoms are the most common reasons patients discontinue most GLP-1 medications. If you have a history of severe GI conditions,microdose GLP-1 injections offer a better starting point.

4. Pregnancy Contraindication

Both drugs should be stopped at least two months before a planned pregnancy. Neither has been evaluated for safety during pregnancy, and animal studies showed adverse fetal outcomes at high doses. 

5. Kidney and Gallbladder Effects

Severe dehydration from GI side effects may increase the risk of acute kidney injury, particularly early in treatment. Both drugs have also been linked to gallbladder disease, including gallstones and cholecystitis. 

Who Might Choose Wegovy?

Wegovy may be the right fit if:

• You want a weight loss drug with direct FDA approval.
• Your provider prefers starting with a single-receptor GLP-1 agonist.
• You've tried lower doses of semaglutide (Ozempic) and tolerated it well. 
• Your insurance specifically covers weight loss medications like Wegovy.

For more on how Wegovy compares with other options, read our detailed comparison guide on Wegovy vs. Ozempic and Mounjaro.

Who Might Choose Mounjaro?

Mounjaro may be a better fit if:

• Weight loss is the primary goal, and you want the strongest results from a dual receptor agonist peptide. 
• Your provider recommends tirzepatide based on your metabolic profile. 
• You're willing to extend the titration period.
• You have a Type 2 diabetes diagnosis.

You can also read our guide for a direct comparison between Semaglutide vs. Mounjaro.

Can You Switch Between Them?

Yes. But only under medical supervision.

Some patients start on Wegovy and switch to Mounjaro after a plateau. Others switch due to side effects, coverage changes, or a provider's clinical recommendation. 

For patients switching from Mounjaro to semaglutide, the same logic applies. 

Start Your Personalized Weight Loss Journey with Ivy Rx
‍

Both Wegovy and Mounjaro are clinically proven. Both produce meaningful weight loss. Without insurance, both are difficult to access.

Ivy Rx offers personalized GLP-1 injections with full medical evaluation and ongoing provider support, and no insurance required. The medication starts at $175 per month only.

And a licensed provider will review your health history and help determine the right option for your goals.

See if you qualify.

FAQs

1. Is Wegovy the Same as Mounjaro?

No. Wegovy contains semaglutide; Mounjaro contains tirzepatide. Both are GLP-1 medications, but they have different active ingredients, mechanisms of action, and FDA-approved uses.

2. When Is Tirzepatide Used to Treat Diabetes?

Tirzepatide is approved under the brand name Mounjaro for the management of Type 2 diabetes in adults. It improves blood sugar control through dual GLP-1 and GIP receptor activity.

3. Are Wegovy and Mounjaro Covered by Insurance?

Sometimes. Mounjaro is more commonly covered for patients with a Type 2 diabetes diagnosis. Wegovy coverage for weight management varies widely by plan and is often limited or excluded altogether.

‍